Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BIIB
BIIB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BIIB News
Three Stocks with Upgraded Ratings as Markets Reach New Highs
2d ago
NASDAQ.COM
Biogen Faces Challenges but Future Potential Remains
3d ago
Fool
Biogen's Quarterly Performance Lags, Future Uncertain
3d ago
NASDAQ.COM
Biogen Shares Rise After Upgrade and Acquisition Announcement
5d ago
seekingalpha
Biogen Upgraded by Piper Sandler, Growth Prospects Remain Positive
5d ago
CNBC
Latest Rating Changes on Wall Street
5d ago
CNBC
Morgan Stanley Raises Biogen Price Target to $200
Apr 11 2026
Yahoo Finance
A Doctor's Journey with His Son's Rare Disease
Apr 09 2026
CNBC
ALLOY: BIOGEN TO UTILIZE PLATFORM IN COLLABORATION TO FURTHER ANTISENSE THERAPEUTICS FOR SEVERAL UNDISCLOSED TARGETS
Apr 07 2026
moomoo
ALLOY THERAPEUTICS ANNOUNCES MULTI-TARGET COLLABORATION AND LICENSE DEAL WITH BIOGEN FOR ALLOY'S ANTICLASTIC™ ASO PLATFORM
Apr 07 2026
moomoo
Biogen Plans $34 Million Charge Impacting Q1 Earnings
Apr 07 2026
Fool
Biogen Plans to Book $34 Million Charge in Q1
Apr 07 2026
NASDAQ.COM
Market Capitalization Analysis of American Water Works
Apr 06 2026
NASDAQ.COM
Biogen Expects Q1 EPS Impact of $0.19 Due to R&D Charges
Apr 06 2026
seekingalpha
Biotech Landscape Update: Regulatory Approvals and Acquisitions
Apr 03 2026
NASDAQ.COM
Biogen's $5.6 Billion Acquisition of Apellis Pharmaceuticals Fails to Boost Stock Price
Apr 01 2026
Fool
Show More News
